Mixed results for delistings in Singapore

Templeton questions MBKÆs offer to buy out minority shareholders in AsiaPharm, while TecityÆs plan to delist Straits Trading gets a fillip as the competing bidder withdraws.

Delisting hopefuls in Singapore have achieved mixed results this week with MBK hitting a hurdle in its $252 million plan to delist AsiaPharm, and Tecity moving a step forward in its $1.5 billion bid for Straits Trading.

The bid by private equity firm MBK Partners for AsiaPharm was in focus yesterday when Templeton Asset Management president Mark Mobius said the fund was ônot convinced by the offerö. Mobius says the offer price ôseverely undervalues AsiaPharm and is...

FinanceAsia has updated its subscription model. Registered readers now have the opportunity to read five articles from our award-winning website for free. Please subscribe for unlimited access.

Click for more on: asiapharm | mbk | templeton | mark mobius | straits trading | tecity | ocbc

Print Edition

FinanceAsia Print Edition